Author(s): Daniel Benhuri, Yesha Patel Rana, and Thida Aye
Factor Xa inhibitors are approved for the prevention of clot formation in non-valvular atrial fibrillation and for treating deep venous thromboembolism and pulmonary embolism. This class of medications are known CYP3A4 and CYP2J2 inhibitors vulnerable to drug-drug interactions and are known to be risk factors for GI bleeding. Although not a common finding, these medications are possible risk factors for acute liver injury, as seen in our patient. We present an uncommon case of persistent Factor Xa Inhibitor induced liver injury in an Eastern Asian male.
